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Case presentation 
 
A 56-year-old male patient with a history of Friedreich ataxia was referred to the 
cardiac catheterization laboratory after electromechanical resuscitation due to 
ventricular fibrillation. Two hours before, trans-urethral intra-vesical botulinum toxin A 
injection (300 units) had been performed because of neurogenic bladder dysfunction. 
His past medical history was positive for hypertension and smoking, but negative for 
any cardiovascular event.   
On admission, laboratory analysis had been unremarkable and baseline ECG 
showed incomplete right bundle branch block and T-wave inversions in leads V1-V2. 
Postrescuscitation, new preterminal T-wave inversions were noted in the inferior 
leads and in leads I, and V3-6, along with troponin T elevation (0.72 µg/l). In the 
course, dynamic discrete ST-segment elevations developed in leads V1-V3. 
Unfractionated heparin, acetylsalicylic acid and clopidogrel were administered for 
suspected acute coronary syndrome. Coronary angiography revealed thrombotic 
occlusion of the right coronary artery with a large thrombus extending from the 
proximal to the mid segment (Figure A). Of note, there were no coronary artery 
spasms observed; in particular, vascular tone was unchanged after intracoronary 
nitroglycerine administration. Immediate percutaneous coronary intervention was 
performed and the vessel reopened by means of thrombus aspiration using a diver 
catheter and the utilization of two drug-eluting stents (Biomatrix). Final angiographic 
documentation revealed complete restoration of flow and normal left ventricular wall 
motions with preserved left ventricular systolic function (Figure B). The post-
interventional course on the ICU was unremarkable and the patient was transferred 
to the regular ward one day after admission.  
 
 Discussion 
 
We describe a case of acute myocardial infarction in a patient with Friedreich 
ataxia following intra-vesical botulinum toxin A injection.  
Cardiac involvement is frequently observed in Friedreich ataxia. However, acute 
coronary syndromes have rarely been described in these patients. Typically, 
hypertrophic cardiomyopathy, which was excluded in our patient using 
echocardiography, and an abnormal repolarization phase and arrhythmias are 
detected (1).  
Botulinum toxin A impedes neuromuscular transmission causing muscle 
weakening. It blocks acetylcholine release in nerve terminals by cleaving SNARE 
proteins, thereby preventing fusion of acetylcholine vesicles with the cell membrane. 
Botulinum toxin A is widely used for cosmetic applications, in the treatment of muscle 
spasms, chronic pain syndroms, or bladder dysfunction (2). 
Botulinum toxin A is assumed to have mainly local effects. However, systemic 
side effects have been described. Hence, botulinum toxin A might also affect 
vasoreactivity or interact with the coagulation cascade, endothelial cells or platelets 
and in turn promote thrombus formation. Indeed, single cases of myocardial 
infarction, pulmonary embolism, and even death have been reported after botulinum 
toxin A injection (3). The effect of botulinum toxin A on vasoreactivity is not fully 
understood. In rat aortic rings suspended in organ chambers, contractions to KCl and 
norepinephrine were completely inhibited after incubation with botulinum toxin (4). 
Furthermore, in Sprague-Dawley rats, femoral vessel diameter was increased after 
subcutaneous botulinum toxin injection (5). Hence, and in line with the coronary 
angiogram, vasospasms as the primary cause of the acute myocardial infarction 
appear unlikely in this patient. Rather, the extensive thrombus burden, suggests a 
pro-thrombotic state. As we did not exclude a patent foramen ovale in our patient, 
paradoxical embolism can not be ruled out completely. However, such events are 
rare and typically present with abrupt distal coronary occlusion suggestive of 
embolism on angiogram. In any case, pro-thrombotic effects of botulinum toxin A 
have not been described so far, both, in vitro and in vivo, and may be assumed.  
The temporal coincidence of botulinum toxin injection and the onset of 
myocardial infarction in our patient suggest a causal relationship. Importantly, as 
botulinum toxin injections are widely performed, also in elderly patients with 
cardiovascular disease, and as acute coronary syndromes are serious complications, 
clinicians should be cautious using botulinum toxin A because of the risk of serious 
side effects and patients have to be monitored carefully after botulinum toxin 
injections.     
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Figure legends 
 
Figure: A. Coronary angiography revealing thrombotic occlusion of proximal and mid 
segments of the right coronary artery with collateral flow from the left anterior 
descending artery. B. Coronary angiography of the right coronary artery following 
percutaneous coronary intervention. 
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